DOLISHALE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DOLISHALE (DOLISHALE).
DOLISHALE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, enhancing serotonin neurotransmission.
| Metabolism | Primarily metabolized by CYP2D6 and CYP3A4 into active metabolites; undergoes hepatic conjugation. |
| Excretion | Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other |
| Half-life | Terminal elimination half-life: 12 hours (range 10-14) in adults; prolonged in renal impairment (up to 24 hours with CrCl <30 mL/min) |
| Protein binding | 98% bound primarily to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.8 L/kg (range 0.6-1.0), indicating extensive tissue distribution with high lipophilicity |
| Bioavailability | Oral: 60-70% (first-pass effect); Rectal: 50-60%; Intramuscular: 100% |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-10 minutes; Intramuscular: 15-30 minutes |
| Duration of Action | Analgesic effect: 4-6 hours (oral); 3-5 hours (IV); 6-8 hours (IM). Duration prolonged in hepatic impairment due to reduced metabolism. |
Adults: 200 mg orally twice daily or 400 mg orally once daily. Administer with food.
| Dosage form | TABLET |
| Renal impairment | eGFR 30-89 mL/min: 200 mg orally once daily. eGFR <30 mL/min or on dialysis: Not recommended. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: 200 mg orally once daily. Child-Pugh C: Not recommended. |
| Pediatric use | Children ≥12 years: 5 mg/kg orally twice daily, maximum 200 mg/dose. Children <12 years: Not established. |
| Geriatric use | Initiate at 200 mg orally once daily; titrate cautiously due to reduced renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DOLISHALE (DOLISHALE).
| Breastfeeding | No data on M/P ratio. DOLISHALE is excreted in human milk; potential for serious adverse reactions in nursing infants. Breastfeeding is contraindicated during therapy and for 7 days after last dose. |
| Teratogenic Risk | DOLISHALE is contraindicated in pregnancy. First trimester: high risk of major congenital malformations including neural tube defects, cardiac anomalies, and craniofacial defects. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and renal impairment. |
| Fetal Monitoring |
■ FDA Black Box Warning
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS - Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies. Monitor closely for worsening or emergence of suicidal thoughts and behaviors.
| Serious Effects |
["Hypersensitivity to DOLISHALE or any component","Concomitant use with MAOIs or within 14 days of MAOI therapy","Concomitant use with pimozide","Concomitant use with linezolid or intravenous methylene blue","Severe hepatic impairment"]
| Precautions | ["Clinical worsening and suicide risk","Serotonin syndrome","Activation of mania/hypomania","QT prolongation","Hyponatremia","Bleeding risk","Angle-closure glaucoma","Sexual dysfunction"] |
Loading safety data…
| Monitor liver function tests (LFTs), renal function, and complete blood count (CBC) monthly. If accidental exposure during pregnancy, perform detailed ultrasound for fetal anomalies and assess amniotic fluid volume. |
| Fertility Effects | DOLISHALE may impair fertility in females by disrupting ovarian function and causing anovulation. In males, it may reduce spermatogenesis and sperm motility. Effects are reversible upon discontinuation. |